Related Experiment Video

Updated: Jul 26, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative

J S Fischer1, R L Priore, L D Jacobs

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, OH, USA.

Annals of Neurology
|December 16, 2000
PubMed

Insights

Interferon beta-1a (IFNbeta-1a) treatment significantly improved cognitive function in relapsing multiple sclerosis (MS) patients, particularly in information processing and learning/memory domains over two years.

Area of Science:

  • Neuroimmunology
  • Neuropsychology
  • Clinical Neurology

Background:

  • Cognitive dysfunction is a prevalent and debilitating symptom in multiple sclerosis (MS).
  • Limited research exists on the impact of therapeutic interventions on neuropsychological (NP) outcomes in MS patients.
  • Understanding treatment effects on cognition is crucial for managing MS progression and patient quality of life.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a (IFNbeta-1a) in improving cognitive function in patients with relapsing MS.
  • To assess the long-term effects of intramuscular IFNbeta-1a on specific neuropsychological domains.
  • To determine if IFNbeta-1a influences the rate of cognitive decline in MS.

Main Methods:

  • A phase III clinical trial involving 166 relapsing MS patients who completed 2-year assessments.
  • Administration of a Comprehensive Neuropsychological (NP) Battery at baseline and week 104.
  • Grouping of NP outcomes into information processing/learning/memory (Set A), visuospatial/problem-solving (Set B), and verbal/attention (Set C) domains.

Main Results:

  • IFNbeta-1a demonstrated a significant beneficial effect on the Set A composite score, indicating improved information processing and learning/memory.
  • A favorable trend was observed in Set B (visuospatial abilities and problem-solving), suggesting broader cognitive benefits.
  • Secondary analyses showed significant improvements in Brief NP Battery performance and processing rates, favoring the IFNbeta-1a group.

Conclusions:

  • Intramuscular interferon beta-1a (IFNbeta-1a) provides significant benefits for cognitive function in relapsing multiple sclerosis (MS).
  • The treatment particularly impacts cognitive domains vulnerable to MS, such as information processing and learning/memory.
  • These findings support the use of IFNbeta-1a in managing cognitive impairment associated with relapsing MS.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...